Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash Flows from Operating Activities
Net income	$ 392	$ 755
Adjustments to reconcile net income to net cash flows provided by operating activities:
Depreciation	110	98
Amortization	155	102
Impairment of assets	9	0
Acquired in-process research and development and milestones	6	81
Accretion and changes in fair value in contingent consideration	(9)	0
Deferred income tax expense (benefit)	33	(170)
Stock-based compensation	70	79
Unrealized foreign exchange gain	(8)	(24)
Gain on debt repurchase	(46)	0
Other	60	18
Net changes in assets and liabilities, net of assets acquired
Accounts receivable	(81)	42
Inventories	(94)	(100)
Other current assets	(54)	(180)
Trade accounts payable	(97)	(215)
Accrued and other current liabilities	14	(28)
Income taxes payable	(30)	24
Other	129	67
Net Cash Flows Provided by Operating Activities	559	549
Cash Flows from Investing Activities
Capital expenditures	(117)	(120)
Proceeds from sale of property, plant and equipment	1	2
Acquired in-process research and development and milestones	(10)	(26)
Dermavant acquisition, net of cash acquired	(75)	0
Purchase of product rights and asset acquisition	(124)	(73)
Net Cash Flows Used in Investing Activities	(325)	(217)
Cash Flows from Financing Activities
Proceeds from debt	730	1,036
Repayments of debt	(1,006)	(1,045)
Payment of long-term debt issuance costs	0	(36)
Employee withholding taxes related to stock-based awards	(14)	(18)
Dividend payments	(84)	(223)
Net Cash Flows Used in Financing Activities	(374)	(286)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	137	24
Net (Decrease) Increase in Cash and Cash Equivalents	(3)	70
Cash and Cash Equivalents, Beginning of Period	675	693
Cash and Cash Equivalents, End of Period	$ 672	$ 763